Contribution of Bradykinin B2 Receptors to the Inhibition by Valsartan of Systemic and Renal Effects of Exogenous Angiotensin II in Salt-Repleted Humans
Open Access
- 1 September 2010
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 334 (3) , 911-916
Abstract
To investigate whether bradykinin (BK) participates in the inhibition of renal effects of exogenous angiotensin II (AngII) by AngII type 1 receptor (AT1R) blockade, eight salt-repleted volunteers underwent four p-aminohippurate- and inulin-based renal studies of AngII infusion at increasing rates of 0.625, 1.25, and 2.5 ng·kg·min−1 for 30 min. Studies 1 and 2 were preceded by 3 days of placebo, whereas studies 3 and 4 used 240 to 320 mg·day−1 valsartan. Bradykinin B2-type receptor (BKB2R) antagonist icatibant (50 μg·kg−1) was coinfused in studies 2 and 4. Mean blood pressure (MBP), glomerular filtration rate (GFR), renal blood flow (RBF), and renal sodium excretion (UNaV) were measured. In study 1, MBP rose by 12.8%, UNaV decreased by 68%, and GFR and RBF also fell (p < 0.001 for all). In study 2, GFR and RBF fell as in study 1, but the rise in MBP and the fall in UNaV were accentuated [+20.0%, analysis of variance (ANOVA), p < 0.02 versus study 1 and −80.0%, p < 0.05, respectively]. In study 3, AngII had no effects, and in study 4, renal hemodynamics remained unaffected, but MBP still rose and UNaV fell (ANOVA, p < 0.02 and 0.005 versus study 3, respectively). Icatibant accentuated AngII-induced changes in MBP and UNaV. Previous AT1R blockade prevented any systemic and renal effects of AngII, but significant changes in MBP and UNaV still followed AngII plus icatibant even after AT1R blockade. BK, through BKB2Rs, participates in the inhibitory action of AT1R blockers toward actions of exogenous AngII on MBP and UNaV in healthy humans.Keywords
This publication has 38 references indexed in Scilit:
- Blockade of renal medullary bradykinin B2receptors increases tubular sodium reabsorption in rats fed a normal-salt dietAmerican Journal of Physiology-Renal Physiology, 2008
- Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor BlockadeThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive PatientsHypertension, 2007
- Cardiovascular and Renal Regulation by the Angiotensin Type 2 ReceptorHypertension, 2005
- Endothelin-A Receptors Mediate Renal Hemodynamic Effects of Exogenous Angiotensin II in HumansHypertension, 2003
- AT 1 -Receptor Antagonism Improves Endothelial Function in Coronary Artery Disease by a Bradykinin/B 2 -Receptor-Dependent MechanismHypertension, 2003
- Bradykinin B2Receptor Antagonism Attenuates Blood Pressure Response to Acute Angiotensin-Converting Enzyme Inhibition in Normal MenHypertension, 2000
- Renal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy MenHypertension, 1997
- Losartan Blocks Aldosterone and Renal Vascular Responses to Angiotensin II in HumansHypertension, 1996
- Rat renal interstitial bradykinin, prostaglandin E2, and cyclic guanosine 3',5'-monophosphate. Effects of altered sodium intake.Hypertension, 1994